Jason Johnson
About Jason Johnson
Jason E. Johnson is Encision’s VP of Sales, age 50 as of March 31, 2025; he joined Encision in 2016, became National Sales Director in 2021–2022, and has served as VP Sales since October 2022. He holds a B.S. in Communications/Marketing from the University of Minnesota and has 20+ years of medical industry experience spanning marketing, sales, and communications . During FY 2025, Encision’s total revenue was $6,555,315 vs. $6,585,882 in FY 2024 (down ~0.5%), gross profit rose to $3,511,286 with gross margin improving to 54% of product revenue (from 48%), and net loss narrowed to $(220,198) from $(691,783) in FY 2024, reflecting improved product margins and higher service revenue . Company-level TSR from the pay-versus-performance table shows the value of an initial $100 investment at $147.06 (FY 2022), $61.76 (FY 2023), and $75.00 (FY 2024) .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Encision Inc. | Regional Sales Director (multiple regions) | 2016–2021 | Led regional sales; background in marketing, sales, communications |
| Encision Inc. | National Sales Director | 2021–2022 | Directed national sales organization |
| Encision Inc. | VP of Sales | Oct 2022–present | Oversees U.S. sales and distribution; national accounts focus |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Not disclosed | — | — | No external public-company directorships disclosed in proxy biographies |
Fixed Compensation
| Metric | FY 2024 | FY 2025 |
|---|---|---|
| Base Salary ($) | 187,379 | 194,132 |
| Bonus ($) | 0 | 0 |
| Stock Awards ($) | 0 | 0 |
| Option Awards ($) | 0 | 0 |
| All Other Compensation ($) | 6,000 | 6,000 |
| Total ($) | 193,379 | 200,132 |
Performance Compensation
Current-Year Equity Grants (FY 2025)
| Name | Grant Date | Award Type | Shares/Options (#) | Strike/Terms | Grant-Date Fair Value ($) | Notes |
|---|---|---|---|---|---|---|
| Jason E. Johnson | — | Options | — | — | — | No FY 2025 option grant to Johnson |
Outstanding Options at FY-End 2025 (Vesting/Expiration detail)
| Exercisable (#) | Unexercisable (#) | Exercise Price ($/Sh) | Expiration Date |
|---|---|---|---|
| 5,000 | — | 0.55 | 05/25/2025 |
| 7,167 | 2,833 | 0.80 | 11/11/2026 |
| 4,833 | 5,167 | 0.45 | 01/19/2028 |
Equity Ownership & Alignment
| Data Point | Value |
|---|---|
| Shares Beneficially Owned (as of 6/23/2025) | 13,667 |
| Ownership % of Outstanding (11,879,645 shares) | 0.12% |
| Notes on Composition | Includes 13,667 shares issuable pursuant to options exercisable within 60 days |
| Rule 10b5-1 Trading Plans | None in effect during FY 2025 for directors/executive officers |
| Insider Trading/Pledging Policy | Policy warns of risks from margin accounts/pledging and prohibits derivative transactions by officers/directors |
Employment Terms
- No employment agreement, severance, change-of-control, or clawback provisions specific to Jason Johnson are disclosed in the DEF 14A; employment agreement details disclosed pertain to the CEO (Gregory Trudel) only .
Investment Implications
- Alignment and equity leverage: Johnson received no new equity grants in FY 2025 and has modest beneficial ownership (0.12%), primarily via options exercisable within 60 days—suggesting limited equity-based alignment relative to peers; monitoring future grants is key for retention and incentive alignment .
- Vesting/expiration-driven selling dynamics: With outstanding options expiring 11/11/2026 and 01/19/2028, exercise decisions could create episodic selling pressure; absence of 10b5-1 plans in FY 2025 means any sales may be opportunistic rather than pre-scheduled .
- Company performance context: FY 2025 saw gross margin improvement (54% of product revenue vs. 48% in FY 2024) and a materially lower net loss ($(220,198) vs. $(691,783)), which enhances the backdrop for sales execution while total revenue was roughly flat; if margin gains persist, variable comp adoption for the sales organization could strengthen pay-for-performance alignment .
- Governance and trading risk: Insider policy restricts derivatives and flags pledging risks; continued absence of pledging disclosures reduces a key red flag, but ongoing monitoring of Forms 3/4/5 and proxy updates is warranted .